Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
通过血浆置换和放射治疗治疗黑色素瘤克服免疫检查点抑制
基本信息
- 批准号:10188955
- 负责人:
- 金额:$ 20.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-05 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:Abscopal effectAffectAntibodiesAntigen-Presenting CellsAutoimmune DiseasesBindingBloodBlood CirculationCD8-Positive T-LymphocytesCD8B1 geneCancer HistologyCell surfaceCellsCleaved cellClinicalClinical TrialsDevelopmentExcisionFamilyFutureGoldGranzymeHourImmuneImmune checkpoint inhibitorImmune responseImmunityImmunotherapyInferiorInflammatoryKineticsLeadLesionMajor Histocompatibility ComplexMalignant NeoplasmsMediatingMedicalMetalloproteasesMetastatic MelanomaMethodsModalityMultiple SclerosisMyasthenia GravisNatural regenerationNeoplasm MetastasisOutcomePD-1 inhibitorsPD-1/PD-L1PDL1 inhibitorsPatientsPlasmaPlasmapheresisProceduresProductionRNA SplicingRadiation therapyRandomized Clinical TrialsRefractoryReportingResistanceResistance developmentSafetySignal TransductionSurfaceT-LymphocyteTestingTherapeuticTherapeutic EffectTranslatingTreatment ProtocolsTumor ImmunityVariantanti-PD-1anti-PD-L1anti-PD1 antibodiesanti-melanoma immunitycheckpoint inhibitionchemotherapycytokinecytotoxicdesigneffector T cellextracellularextracellular vesiclesimmunoregulationimprovedinhibitor/antagonistmelanomaneoantigensneoplastic cellnovelnovel therapeuticsperipheral bloodprogrammed cell death ligand 1programmed cell death protein 1prospectiveradiation resistancereceptorrecruitresponsesurvival outcometumor
项目摘要
ABSTRACT
PD-1-directed immune checkpoint inhibitors (ICI) have significantly improved survival in metastatic melanoma
compared to traditional chemotherapy. Unfortunately, less than half of patients with melanoma respond to ICI
treatment. Anti-PD1/PD-L1 ICI resistance extends beyond melanomas, resulting in a meager 15-35% response
rate for most cancers. Melanomas secrete factors that lead to ICI resistance, including soluble PD-L1 (sPD-L1)
and PD-L1-positive extracellular vesicles (evPD-L1). We recently discovered that both sPD-L1 and evPD-L1 in
the peripheral blood directly kill effector CD8+ T cells through interaction with the PD-1 receptor (Fig 4). They
also indirectly “quench” the available therapeutic anti-PD-1 antibody resulting in low ICI response rates (Fig 5).
Thus, there is an urgent need to remove these soluble forms from circulation to rescue patients with melanoma
from ICI resistance.
We have previously shown that stereotactic body radiotherapy (SBRT) can improve systemic immune
responses, known as “abscopal effect.” Abscopal effect is the result of SBRT inducing neoantigens, pro-
inflammatory cytokines, and up-regulating major histocompatibility complex and B7 family co-stimulatory
molecules on antigen presenting cells to recruit effector T cells. Unfortunately, abscopal effect is rarely observed
in patient, and therefore, ICI and radiotherapy combination studies are ongoing. While SBRT activates anti-
melanoma immunity by providing neoantigens and danger signals, tumors release these immunosuppressive
extracellular forms of PD-L1 that kill activated effector T cells (Fig 1). Radiotherapy increases tumor sPD-
L1/evPD-L1 release, and we have reported that high plasma sPD-L1 and/or evPD-L1 levels portend poor
response to therapy and survival.
Recently, we have discovered that therapeutic plasma exchange (TPE), a safe and commonly performed
procedure for other medical indications (e.g. autoimmune diseases, myasthenia gravis, multiple sclerosis, etc),
removes both sPD-L1 and evPD-L1 safely from the circulation. Therefore, we hypothesize that the removal of
circulating sPD-L1 and evPD-L1 by TPE may overcome PD-L1/PD-1-mediated immune regulation to improve
ICI + SBRT response rates and survival in patients with metastatic melanoma. If successful, our proposed
concept can be readily investigated in a prospective randomized clinical trial and involve many centers that
routinely perform TPE. Furthermore, our novel concept can be explored in other cancer histologies with PD-
L1/PD-1 resistance where elevated sPD-L1 and evPD-L1 are detected in patients’ blood.
Figure 1: Extracellular forms of PD-L1 (1) evPD-L1 and (2) sPD-L1 cause resistance to PD-(L)1 inhibitor
therapy in cancer by outcompeting PD-(L)1 inhibitors and killing CD8+ effector T cells (see also Figure 4).
The availability of therapeutic anti-PD-L1 inhibitors is “quenched” by soluble PD-L1 and evPD-L1 released
from tumor cells which limits its availability. Furthermore, sPD-L1 and evPD-L1 can bind to T cell surface
PD-1 receptors and outcompete anti-PD-1 inhibitors.
Radiotherapy
Tumor Cell
1
PD-L1+ EVs
PD1
Immune Cell
PD-L1-Inhibitor
ADAM10/
ADAM17
2
PD-L1sPD-L1
PD-1-Inhibitor PD1
摘要
PD-1导向的免疫检查点抑制剂(ICI)可显著改善转移性黑色素瘤的生存期
与传统化疗相比。不幸的是,不到一半的黑色素瘤患者对ICI有反应,
治疗抗PD 1/PD-L1 ICI耐药性超出黑色素瘤,导致应答率仅为15-35%
对于大多数癌症来说。黑色素瘤分泌导致ICI抗性的因子,包括可溶性PD-L1(sPD-L1)
和PD-L1阳性细胞外囊泡(evPD-L1)。我们最近发现sPD-L1和evPD-L1在
外周血通过与PD-1受体的相互作用直接杀死效应CD 8 + T细胞(图4)。他们
也间接“淬灭”可用的治疗性抗PD-1抗体,导致低ICI应答率(图5)。
因此,迫切需要将这些可溶性形式从循环中去除以拯救黑素瘤患者
从ICI抵抗。
我们先前已经表明,立体定向体部放疗(SBRT)可以改善全身免疫功能,
反应,称为“远位效应”。远位效应是SBRT诱导新生抗原的结果,
炎性细胞因子,上调主要组织相容性复合物和B7家族共刺激因子,
抗原呈递细胞上的分子以募集效应T细胞。不幸的是,远位效应很少被观察到
因此,ICI和放疗联合研究正在进行中。SBRT激活抗-
黑色素瘤免疫通过提供新抗原和危险信号,肿瘤释放这些免疫抑制因子,
细胞外形式的PD-L1杀死活化的效应T细胞(图1)。放射治疗增加肿瘤sPD-
L1/evPD-L1释放,我们已经报道了高血浆sPD-L1和/或evPD-L1水平预示着不良的
对治疗和生存的反应。
最近,我们发现治疗性血浆置换(TPE)是一种安全且常用的方法,
其他医学适应症(例如,自身免疫性疾病、重症肌无力、多发性硬化等)的手术,
将sPD-L1和evPD-L1安全地从循环中清除。因此,我们假设,
通过TPE循环sPD-L1和evPD-L1可以克服PD-L1/PD-1介导的免疫调节,
转移性黑色素瘤患者的ICI + SBRT缓解率和生存率如果成功,我们的建议
概念可以在前瞻性随机临床试验中很容易地进行研究,并涉及许多中心,
定期进行TPE。此外,我们的新概念可以在其他PD癌症组织学中进行探索-
L1/PD-1耐药,在患者血液中检测到sPD-L1和evPD-L1升高。
图1:PD-L1的细胞外形式(1)evPD-L1和(2)sPD-L1导致对PD-(L)1抑制剂的耐药性
通过竞争性胜过PD-(L)1抑制剂并杀死CD 8+效应T细胞,在癌症治疗中发挥重要作用(也参见图4)。
治疗性抗PD-L1抑制剂的可用性被释放的可溶性PD-L1和evPD-L1“淬灭”
这限制了它的可用性。此外,sPD-L1和evPD-L1可以结合到T细胞表面
PD-1受体和胜过抗PD-1抑制剂。
放疗
肿瘤细胞
1
PD-L1+ EV
PD1
免疫细胞
PD-L1抑制剂
ADAM 10/
Adam17
2
PD-L1
PD-1-抑制剂PD 1
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Orme其他文献
Jacob Orme的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacob Orme', 18)}}的其他基金
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
通过血浆置换和放射治疗治疗黑色素瘤克服免疫检查点抑制
- 批准号:
10343851 - 财政年份:2021
- 资助金额:
$ 20.19万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 20.19万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Studentship